Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | AGXT | P21549 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405407 | 0.83 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL4048647 | 0.83 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL11706351 | 0.83 | LOXL2 (0.46) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL14075637 | 0.82 | LOXL2 (0.69) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL6214405 | 0.80 | LOXL2 (0.56) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL4049122 | 0.79 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL4386951 | 0.79 | LOXL2 (0.55) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL5793787 | 0.79 | LOXL2 (0.55) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL16549715 | 0.78 | LOXL2 (0.64) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL3026368 | 0.78 | LOXL2 (0.64) | LOXL2AGXTHTR2BHTR1ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-12240812-B2 | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2025-03-04 | — | — | US | disclosed |
| EP-3889134-B1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | KEYTHERA SUZHOU PHARMACEUTICALS CO LTD (CN) | 2024-09-25 | — | — | EP | disclosed |
| US-20240294511-A1 | SOLID FORM OF INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | KEYTHERA (SUZHOU) BIO-PHARMACEUTICALS CO., LIMITED (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4393906-A1 | SOLID FORM OF INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Keythera (Suzhou) Bio-Pharmaceuticals Co., Limited (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-118047780-A | Quinazoline heterocyclic compound and anti-infection and anti-tumor application thereof | 中国医学科学院药物研究所 | 2024-05-17 | — | — | CN | disclosed |
| CN-117940403-A | Solid form of indole compound, preparation method and application thereof | 凯复(苏州)生物医药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-5554641-A | Nonpeptides as tachykinin antagonists | WARNER-LAMBERT COMPANY | 1996-09-10 | — | — | US | disclosed |
| WO-1996004254-A2 | BENZODIAZEPINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-15 | — | — | WO | disclosed |
| US-5414013-A | Enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| US-5414017-A | Cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0449523-B1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | SQUIBB & SONS INC (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5223516-A | Endopeptidase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0449523-A1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | E.R. SQUIBB & SONS, INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-4794188-A | LIPOXYGENASE INHIBITORS | USV PHARMACEUTICAL CORPORATION (US) | 1988-12-27 | — | — | US | disclosed |
| US-4594425-A | Benzimidazole, benzoxazole or benzothiazole compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-06-10 | — | — | US | disclosed |
| US-4002423-A | Benzofuran derivatives process for their preparation and their use as optical brighteners | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | LOXL2 1159/4885AGXT 2494/4885HTR2B 1552/4885 |
| US-20240294511-A1 | SOLID FORM OF INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TPH1, IDO1, INMT | LOXL2 2313/4885AGXT 1095/4885HTR2B 248/4885 |
| US-12240812-B2 | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof | PTGER4, PTGER1, PTGES | LOXL2 814/4885AGXT 3154/4885HTR2B 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.